Mukherjee O, Rakshit S, Shanmugam G, Sarkar K
Curr Res Immunol. 2023; 4:100068.
PMID: 37692091
PMC: 10491645.
DOI: 10.1016/j.crimmu.2023.100068.
El-Tanani M, Nsairat H, Mishra V, Mishra Y, Aljabali A, Serrano-Aroca A
Int J Mol Sci. 2023; 24(4).
PMID: 36834476
PMC: 9968026.
DOI: 10.3390/ijms24043065.
Qattan M, Khan M, Alharbi S, Verma A, Al-Saeed F, Abduallah A
Molecules. 2022; 27(24).
PMID: 36557997
PMC: 9788613.
DOI: 10.3390/molecules27248864.
Antoch M, Wrobel M, Gillard B, Kuropatwinski K, Toshkov I, Gleiberman A
Oncotarget. 2020; 11(15):1373-1387.
PMID: 32341756
PMC: 7170500.
DOI: 10.18632/oncotarget.27550.
Maurya A, Vinayak M
PLoS One. 2016; 11(8):e0160686.
PMID: 27494022
PMC: 4975451.
DOI: 10.1371/journal.pone.0160686.
G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling.
Riaz A, Huang Y, Johansson S
Int J Mol Sci. 2016; 17(2):215.
PMID: 26861299
PMC: 4783947.
DOI: 10.3390/ijms17020215.
Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma.
Kurth I, Hein L, Mabert K, Peitzsch C, Koi L, Cojoc M
Oncotarget. 2015; 6(33):34494-509.
PMID: 26460734
PMC: 4741468.
DOI: 10.18632/oncotarget.5417.
Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.
Sun N, Huang S, Chang P, Lu H, Chao C
Oncotarget. 2014; 5(23):11939-56.
PMID: 25460502
PMC: 4322968.
DOI: 10.18632/oncotarget.2654.
Turning off AKT: PHLPP as a drug target.
Newton A, Trotman L
Annu Rev Pharmacol Toxicol. 2014; 54:537-58.
PMID: 24392697
PMC: 4082184.
DOI: 10.1146/annurev-pharmtox-011112-140338.
Downregulation of PHLPP expression contributes to hypoxia-induced resistance to chemotherapy in colon cancer cells.
Wen Y, Stevens P, Gasser M, Andrei R, Gao T
Mol Cell Biol. 2013; 33(22):4594-605.
PMID: 24061475
PMC: 3838188.
DOI: 10.1128/MCB.00695-13.
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Huang S, Li C, Armstrong E, Peet C, Saker J, Amler L
Cancer Res. 2012; 73(2):824-33.
PMID: 23172311
PMC: 7254871.
DOI: 10.1158/0008-5472.CAN-12-1611.
Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in β1 integrin-mediated cell survival.
Riaz A, Stephanie Zeller K, Johansson S
PLoS One. 2012; 7(2):e32081.
PMID: 22384145
PMC: 3284553.
DOI: 10.1371/journal.pone.0032081.
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
Delbaldo C, Albert S, Dreyer C, Sablin M, Serova M, Raymond E
Target Oncol. 2011; 6(2):119-24.
PMID: 21533544
DOI: 10.1007/s11523-011-0177-6.
Cell-type-specific regulation of raft-associated Akt signaling.
Liu Y, Yang G, Bu X, Liu G, Ding J, Li P
Cell Death Dis. 2011; 2:e145.
PMID: 21490677
PMC: 3122059.
DOI: 10.1038/cddis.2011.28.
Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.
Hu Y, Sun H, Owens R, Gu Z, Wu J, Chen Y
Neoplasia. 2010; 12(10):826-36.
PMID: 20927321
PMC: 2950332.
DOI: 10.1593/neo.10586.
